Results from a phase 1/2, first-in-human, dose escalation and dose expansion study of an investigational anti-ADAM9 antibody-drug conjugate IMGC936 in patients with advanced solid tumors

被引：0
|
作者：
Subbiah, V. [1 ]
Falchook, G. [2 ]
Davis, A. A. [3 ]
Wang, J. S. [4 ]
de Miguel, M. [5 ]
Santoro, A. [6 ]
Maur, M. [7 ]
Aljumaily, R. [8 ]
Boni, V. [9 ]
de Speville, B. Doger [10 ]
Sun, Y. [11 ]
Du, Y. [12 ]
Lakshmikanthan, S. [13 ]
Bedse, G. [14 ]
Ward, A. [15 ]
Zweidler-McKay, P. [11 ]
Gandhi, L. [16 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX USA
[2] HealthONE, Sarah Cannon Res Inst, Dept Drug Dev, Denver, CO USA
[3] Washington Univ St Louis, Div Oncol, St Louis, MO USA
[4] Florida Canc Specialists Sarah Cannon Res Inst, Drug Dev Unit, Sarasota, FL USA
[5] START Madrid CIOCC HM Sanchinarro, Early Phase Clin Trial Program, Madrid, Spain
[6] Humanitas Univ, Dept Biomed Sci, Humanitas Canc Ctr, IRCCS Humanitas Res Hosp, Milan, Italy
[7] Azienda Osped Univ Policlin Modena, Div Oncol, Modena, Italy
[8] Univ Oklahoma, Sect Hematol Oncol, Stephenson Canc Ctr, Hlth Sci Ctr, Oklahoma City, OK USA
[9] NEXT Madrid Univ Hosp Quironsalud, Oncol Early Drug Dev Unit, Madrid, Spain
[10] START Madrid FJD Hosp Univ Fdn Jimenez Diaz, Early Phase Clin Trials Unit, Madrid, Spain
[11] ImmunoGen Inc, Clin Dev, Waltham, MA USA
[12] ImmunoGen Inc, Biostat, Waltham, MA USA
[13] ImmunoGen Inc, Translat Med, Waltham, MA USA
[14] ImmunoGen Inc, Clin Pharmacol, Waltham, MA USA
[15] MacroGenics Inc, Clin Dev, Rockville, MD USA
[16] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114703
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB170
引用
收藏
页码：S72 / S73
页数：2
相关论文
共 50 条
  • [21] First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
    Pegram, Mark D.
    Hamilton, Erika P.
    Tan, Antoinette R.
    Storniolo, Anna Maria
    Balic, Kemal
    Rosenbaum, Anton, I
    Liang, Meina
    He, Peng
    Marshall, Shannon
    Scheuber, Anita
    Das, Mayukh
    Patel, Manish R.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (08) : 1442 - 1453
  • [22] Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors
    Wahlroos, Sara
    Teng, Christina
    Tran, Ben
    Voskoboynik, Mark
    Gan, Hui Kong
    Spencer, Andrew
    Kudva, Anupa
    Song, Ming
    Lynch, Kevin
    Yu, Zhinuan
    Desai, Jayesh
    Lemech, Charlotte Rose
    Lifehouse, Chris O'Brien
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] A first-in-human (FIH) phase 1 study of SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors
    Wang, Jie
    Wu, Lin
    Song, Zhengbo
    Li, Xingya
    Liu, Caigang
    Liu, Tianshu
    Wu, Yiwen
    Zhang, Ze
    Wang, Shuni
    CANCER RESEARCH, 2023, 83 (08)
  • [24] First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors.
    Ameratunga, Malaka
    Harvey, R. Donald
    Mau-Sorensen, Morten
    Thistlethwaite, Fiona
    Forssmann, Ulf
    Gupta, Manish
    Johannsdottir, Hrefna
    Ramirez-Andersen, Terrie
    Bohlbro, Mika Linette
    Losic, Nedjad
    Ervin-Haynes, Annette L.
    Lopez, Juanita Suzanne
    Vergote, Ignace
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] A phase lb, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2.
    Burris, Howard A.
    Barve, Minal A.
    Hamilton, Erika Paige
    Bardia, Aditya
    Soliman, Hatem Hussein
    Jarlenski, Donna
    Mosher, Rebecca
    Bergstrom, Donald Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors
    Duca, Matteo
    Lim, Darren Wan-Teck
    Subbiah, Vivek
    Takahashi, Shunji
    Sarantopoulos, John
    Varga, Andrea
    D'Alessio, Joseph A.
    Abrams, Tinya
    Sheng, Qing
    Tan, Eugene Youchin
    Rosa, Maria Santos
    Gonzalez-Maffe, Juan
    Sand-Dejmek, Janna
    Fabre, Claire
    Martin, Miguel
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (04) : 625 - 634
  • [27] Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study
    Gazzah, A.
    Bedard, P. L.
    Hierro, C.
    Kang, Y-K
    Razak, A. Abdul
    Ryu, M-H
    Demers, B.
    Fagniez, N.
    Henry, C.
    Hospitel, M.
    Soria, J-C
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2022, 33 (04) : 416 - 425
  • [28] A phase I, first-in-human, dose-escalation and dose expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
    Piha-Paul, Sarina Anne
    Wan, Qunfang
    Xiong, Wendy
    Peng, Peng
    Yang, Xiaoju
    Wu, Henry
    Ngo, Brenda
    Wu, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
    Lin, C-C.
    Schneider, R.
    Gutierrez, M.
    Shen, L.
    Chung, K.
    Doroshow, D. B.
    Gao, B.
    Millward, M.
    Hsieh, C-Y.
    Xu, C.
    Cai, S. X.
    Tian, Y. E.
    Liu, L.
    Shen, C.
    Tan, Y.
    He, Y.
    Zhang, C.
    Li, L.
    Ma, M.
    Xu, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S503 - S504
  • [30] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
    Mathiot, Laurent
    Combarel, David
    Cagnat, Justin
    Delahousse, Julia
    Ouali, Kaissa
    Marabelle, Aurelien
    Loriot, Yohann
    Ponce, Santiago
    Champiat, Stephane
    Broutin, Sophie
    Danlos, Francois-Xavier
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
12345